Nasdaq
$0.1788▼ 0.17%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.3MShares out 41.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 10.9After-hours26.10.10 06:158-KKey event#●●●
Vistagen Therapeutics, Inc.
Vistagen Therapeutics amended and restated its Executive Severance Plan effective October 7, 2026. The updated plan expands severance benefits, including cash payments and COBRA premium coverage, to eligible employees upon involuntary termination regardless of whether a change in control occurs.…more
$0.1788-0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25Pre-market26.09.25 22:118-KKey event
Vistagen Therapeutics, Inc.
Vistagen Therapeutics released a new corporate presentation on September 25, 2026. The presentation outlines the clinical status and development strategy for its neuroscience pipeline, including its lead product candidate for social anxiety disorder, fasedienol.…more
$0.1788-0.17%vs prev closeView filingShare - 9.24Pre-market26.09.24 20:058-KKey event
Vistagen Therapeutics, Inc.
Vistagen Therapeutics presented positive exploratory data for its social anxiety disorder candidate, fasedienol, at Psych Congress 2026. Analyses from two clinical trials demonstrated statistically significant improvements in anxiety symptoms and potential benefits of repeat dosing in patients with very severe social anxiety disorder.…more
$0.1788-0.17%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 21:30#●●●#●●●#●●●
Vistagen Partners with GATC Health for AI-Driven Drug Development
Vistagen is collaborating with GATC Health to utilize predictive AI platforms to enhance its clinical-stage drug development programs. This partnership focuses on optimizing clinical trial protocols and resource allocation, though no specific financial terms were disclosed.…more
$0.1788-0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.24Pre-market26.09.24 20:00
●●●●●●●● ●●●●● ●●●●●●
Vistagen announced positive exploratory findings for its nasal spray candidate, fasedienol, in patients with very severe social anxiety disorder. These results are based on post-hoc and exploratory analyses, requiring further clinical validation to confirm efficacy.…more
$0.1788-0.17%vs prev close - 9.22Pre-market26.09.22 21:30
●●●●●●●● ●●●●● ●●●●●●
Vistagen announced positive preliminary safety and efficacy data from the open-label extension of its Phase 3 study for the social anxiety disorder treatment, fasedienol. The company plans to meet with the FDA to discuss a new registrational Phase 3 clinical trial based on these findings.…more
$0.1788-0.17%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report